Everolimus Shows Potential to Enhance Breast Cancer Therapies Findings from a Phase II study show that everolimus (RAD001) enhances tumor shrinkage when given in combination with letrozole tablets (Femara) to postmenopausal women with newly diagnosed estrogen receptor-positive (ER+) breast cancer...
Strong quarterly performance for Novartis LONDON (MarketWatch) -- Novartis on Thursday reported that second-quarter net income increased a stronger-than-expected 21%, helped by growing sales of cancer and cardiovascular drugs.Novartis also affirmed that it expects record sales...
Novartis net profit up by 13% to US$4.6 billion Novartis has posted satisfactory performance during the first half ended June 2008.Its net profit went up by 13 per cent to US$4,574 million from $4,035 million in the corresponding period of last year.
Its net sales increased by 11 per...
Novartis Q2 profit up 12%; backs FY08 forecast - update 2 Swiss healthcare company Novartis AG (NVS: News, Chart, Quote ) reported a 12% rise in its second-quarter profit, driven by strong segmental sales, mainly in Pharmaceuticals and generics subsidiary Sandoz.The company also affirmed its...
Novartis Q2 profit up 12%; backs FY08 forecast Swiss healthcare company Novartis AG (NVS: News, Chart, Quote ) reported a 12% rise in its second-quarter profit, driven by strong segmental sales, mainly in Pharmaceuticals and generics subsidiary Sandoz.The company also affirmed its...
Novartis Q2 profit up 12%; backs FY08 forecast - update 2 Swiss healthcare company Novartis AG (NVS | Quote | Chart | News | PowerRating) reported a 12% rise in its second-quarter profit, driven by strong segmental sales, mainly in Pharmaceuticals and generics subsidiary Sandoz.The company also...
PRESS RELEASE Novartis Gains Momentum With -2- (DJ) healthcare.Net sales from continuing operations for the Group are expected to rise at a mid-single-digit rate, and at a low-single-digit growth rate in the Pharmaceuticals Division, both in local currencies.
Sandoz is now expected to...
Financial Report: Novartis 2Q 2Q Earnings: $2.3 billion (+17%) YTD Revenues: $20.6 billion (+11%) YTD Earnings: $4.6 billion (+13%) Comments: Pharmaceutical sales were $6.9 billion (+14%) in the quarter and $13.2 billion (+10%) in 1H08, driven by Diovan sales along with...
Novartis shows strong Q2 growth Novartis has surpassed estimates for its second quarter performance, boosted by higher than expected sales of its flagship cardiovascular and oncology brands.Strong sales of Glivec and Femara in oncology and Diovan in its...
Novartis shows strong Q2 growth Novartis has surpassed estimates for its second quarter performance, boosted by higher than expected sales of its flagship cardiovascular and oncology brands.Strong sales of Glivec and Femara in oncology and Diovan in its...
PRESS RELEASE Novartis Gains Momentum With -4- (DJ) therapy for patients with cancer that has spread to the bones, was unchanged as fast expansion in some markets offset the US and Europe.Growth for this class of medicines began to slow in 2007 with patients receiving treatment less...
42nd International Childrens Games @ Kezar Stadium Topic - Topic - Loan Online Cigarettes Medical tests Top casino Free Ringtones Medicine news Building materials Cases Intimate goods Bracelets Cheap drugs online shop Ear rings Suits Cars Rolex Replica Cheap pharmacy shop ables Autos...
New inhibitors of breast cancer cells identified What breastcancer.org says about this article Most breast cancers are hormone receptor-positive.The hormone estrogen binds to hormone receptors and in so doing can promote the growth of hormone-receptor-positive breast cancers.
Hormonal...
Letrozole Slows Breast Cancer Long After End of Ta A new study has confirmed that adjuvant therapy with letrozole (Femara, Novartis Pharmaceuticals) can be a powerful weapon for preventing breast cancer recurrence in postmenopausal women with hormone receptorpositive diseaseeven when...
Study shows everolimus may offer novel treatment strategy for breast cancer Early proof-of-concept studies presented at ASCO show RAD001 (everolimus) may offer a novel treatment strategy for breast cancer by enhancing the efficacy of, and overcoming resistance to, several commonly used breast cancer treatments.
Novartis says new data shows RAD001 breast cancer potential ZURICH (Thomson Financial) - Novartis AG said new study data shows that RAD001 may offer a novel treatment strategy for breast cancer by enhancing the efficacy of, and overcoming resistance to, several commonly used breast cancer treatments....
